Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2017, Article ID 4381864, 8 pages
https://doi.org/10.1155/2017/4381864
Research Article

Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients

1Division of Gastroenterology and Hepatology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada
2Division of Gastroenterology and Hepatology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada
3Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada

Correspondence should be addressed to Mamatha Bhat; ac.lligcm.liam@tahb.ahtamam

Received 22 April 2015; Accepted 13 June 2015; Published 19 March 2017

Academic Editor: Eric M. Yoshida

Copyright © 2017 Mamatha Bhat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Firpi, V. Clark, C. Soldevila-Pico et al., “The natural history of hepatitis C cirrhosis after liver transplantation,” Liver Transplantation, vol. 15, no. 9, pp. 1063–1071, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Crespo, S. Lens, M. Gambato et al., “Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C,” American Journal of Transplantation, vol. 14, no. 2, pp. 375–383, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Berenguer and D. Schuppan, “Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment,” Journal of Hepatology, vol. 58, no. 5, pp. 1028–1041, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Bosch, M. G. Heckman, S. Pungpapong, N. N. Diehl, J. A. Shalev, and W. C. Hellinger, “Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation,” Transplantation, vol. 93, no. 7, pp. 723–728, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Seo, K. Maganti, M. Khehra et al., “De novo nonalcoholic fatty liver disease after liver transplantation,” Liver Transplantation, vol. 13, no. 6, pp. 844–847, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Marchetti and R. Navalesi, “The metabolic effects of cyclosporin and tacrolimus,” Journal of Endocrinological Investigation, vol. 23, no. 7, pp. 482–490, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Wali, R. F. Harrison, P. J. Gow, and D. Mutimer, “Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C,” Gut, vol. 51, no. 2, pp. 248–252, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Berenguer, J. M. Rayón, M. Prieto et al., “Are posttransplantation protocol liver biopsies useful in the long term?” Liver Transplantation, vol. 7, no. 9, pp. 790–796, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. D. C. Rockey, S. H. Caldwell, Z. D. Goodman, R. C. Nelson, and A. D. Smith, “Liver biopsy,” Hepatology, vol. 49, no. 3, pp. 1017–1044, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Sebastiani, “Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms,” World Journal of Gastroenterology, vol. 15, no. 18, pp. 2190–2203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Vallet-Pichard, V. Mallet, B. Nalpas et al., “FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest,” Hepatology, vol. 46, no. 1, pp. 32–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Sandrin, B. Fourquet, J.-M. Hasquenoph et al., “Transient elastography: a new noninvasive method for assessment of hepatic fibrosis,” Ultrasound in Medicine and Biology, vol. 29, no. 12, pp. 1705–1713, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. C. Segovia, E. R. Lyden, T. Bernard, and T. M. McCashland, “Evaluation of Fib-4 as a marker of fibrosis in HCV infected patients who underwent liver transplantation,” Hepatology, vol. 48, p. 576A, 2008. View at Google Scholar
  14. A. Pissaia Jr., D. Borderie, D. Bernard, O. Scatton, Y. Calmus, and F. Conti, “APRI and FIB-4 scores are useful after liver transplantation independently of etiology,” Transplantation Proceedings, vol. 41, no. 2, pp. 679–681, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Kamphues, K. Lotz, C. Röcken et al., “Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients,” Clinical Transplantation, vol. 24, no. 5, pp. 652–659, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Bedossa, “Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic Hepatitis C,” Hepatology, vol. 20, no. 1, pp. 15–20, 1994. View at Publisher · View at Google Scholar
  17. E. M. Brunt, C. G. Janney, A. M. Di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions,” American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467–2474, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Yatsuji, E. Hashimoto, M. Tobari, M. Taniai, K. Tokushige, and K. Shiratori, “Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C,” Journal of Gastroenterology and Hepatology, vol. 24, no. 2, pp. 248–254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. WHO, “Obesity: preventing and managing the global epidemic. Report of a WHO Consultation,” WHO Technical Report Series 894, World Health Organization, Geneva, Switzerland, 2000. View at Google Scholar
  20. J. Vergniol, J. Foucher, E. Terrebonne et al., “Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C,” Gastroenterology, vol. 140, no. 7, pp. 1970–1979.e3, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Angulo, E. Bugianesi, E. S. Bjornsson et al., “Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease,” Gastroenterology, vol. 145, no. 4, pp. 782.e4–789.e4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Berenguer, L. Ferrell, J. Watson et al., “HCV-related fibrosis progression following liver transplantation: increase in recent years,” Journal of Hepatology, vol. 32, no. 4, pp. 673–684, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Samuel, X. Forns, M. Berenguer et al., “Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006),” Journal of Hepatology, vol. 45, no. 1, pp. 127–143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Beckebaum, S. Iacob, C. G. Klein et al., “Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients,” Transplantation, vol. 89, no. 8, pp. 983–993, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Toniutto, C. Fabris, D. Bitetto et al., “Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation,” Journal of Gastroenterology and Hepatology, vol. 22, no. 11, pp. 1904–1908, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. AASLD/IDSA/IAS-USA, “Recommendations for testing, managing, and treating hepatitis C,” http://www.hcvguidelines.org
  27. C. G. Child and J. G. Turcotte, “Surgery and portal hypertension,” in The Liver and Portal Hypertension, C. G. Child, Ed., pp. 50–64, Saunders, Philadelphia, Pa, USA, 1964. View at Google Scholar
  28. P. Angulo, J. M. Hui, G. Marchesini et al., “The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD,” Hepatology, vol. 45, no. 4, pp. 846–854, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. T. B. Kelleher, S. H. Mehta, R. Bhaskar et al., “Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index,” Journal of Hepatology, vol. 43, no. 1, pp. 78–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Ahmad, B. Ijaz, F. T. Javed et al., “A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI),” BMC Gastroenterology, vol. 11, article 44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. W. A. Hackworth, D. M. Heuman, A. J. Sanyal et al., “Effect of hyponatraemia on outcomes following orthotopic liver transplantation,” Liver International, vol. 29, no. 7, pp. 1071–1077, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Boin Ide, M. I. Leonardi, E. Y. Udo, T. Seva-Pereira, R. S. Stucchi, and L. S. Leonardi, “The application of MELD score in patients submitted to liver transplantation: a retrospective analysis of survival and the predictive factors in the short and long term,” Arquivos De Gastroenterologia, vol. 45, pp. 275–283, 2008. View at Google Scholar
  33. A. Karapanagiotou, C. Kydona, S. Papadopoulos et al., “The effect of hyponatremia on the outcome of patients after orthotopic liver transplantation,” Transplantation Proceedings, vol. 44, no. 9, pp. 2724–2726, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. M. D. Leise, B. C. Yun, J. J. Larson et al., “Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation,” Liver Transplantation, vol. 20, no. 6, pp. 687–697, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. M.-C. Londoño, M. Guevara, A. Rimola et al., “Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation,” Gastroenterology, vol. 130, no. 4, pp. 1135–1143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Bataller, P. Ginès, J. M. Nicolás et al., “Angiotensin II induces contraction and proliferation of human hepatic stellate cells,” Gastroenterology, vol. 118, no. 6, pp. 1149–1156, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Bataller, P. Sancho-Bru, P. Ginès, and D. A. Brenner, “Liver fibrogenesis: a new role for the renin-angiotensin system,” Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1346–1355, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Bataller, P. Sancho-Bru, P. Ginès et al., “Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II,” Gastroenterology, vol. 125, no. 1, pp. 117–125, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Ikura, M. Ohsawa, N. Shirai et al., “Expression of angiotensin II type 1 receptor in human cirrhotic livers: its relation to fibrosis and portal hypertension,” Hepatology Research, vol. 32, no. 2, pp. 107–116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Hirose, M. Ono, T. Saibara et al., “Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis,” Hepatology, vol. 45, no. 6, pp. 1375–1381, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. R. Jonsson, A. D. Clouston, Y. Ando et al., “Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis,” Gastroenterology, vol. 121, no. 1, pp. 148–155, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Moreno and R. Bataller, “Cytokines and renin-angiotensin system signaling in hepatic fibrosis,” Clinics in Liver Disease, vol. 12, no. 4, pp. 825–852, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. K. W. Burak, W. K. Kremers, K. P. Batts et al., “Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C,” Liver Transplantation, vol. 8, no. 4, pp. 362–369, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. R. R. Razonable, K. W. Burak, H. Van Cruijsen et al., “The pathogenesis of hepatitis C virus is influenced by cytomegalovirus,” Clinical Infectious Diseases, vol. 35, no. 8, pp. 974–981, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. E. J. Gane, “Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences,” American Journal of Transplantation, vol. 12, no. 3, pp. 531–538, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Cárdenas and O. Riggio, “Correction of hyponatraemia in cirrhosis: treating more than a number!,” Journal of Hepatology, vol. 62, no. 1, pp. 13–14, 2016. View at Publisher · View at Google Scholar · View at Scopus